Loading…
TERIPARATIDE SUN is a brand name for Teriparatide. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Teriparatide SUN is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non- vertebral fractures but not hip fractures has been demonstrated. Treatment of…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology The recommended dose of Teriparatide SUN is 20 micrograms administered once daily. 4). The 24-month course of Teriparatide SUN should not be repeated over a patient’s lifetime. Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate.
Following cessation of Teriparatide SUN therapy, patients may be continued on other osteoporosis therapies. 3). In patients with moderate renal impairment, Teriparatide SUN should be used with caution. No special caution is required for patients with mild renal impairment.
3). Therefore, Teriparatide SUN should be used with caution. Paediatric population and young adults with open epiphyses The safety and efficacy of Teriparatide SUN in children and adolescents less than 18 years has not been established.
Teriparatide SUN should not be used in paediatric patients (less than 18 years), or young adults with open epiphyses. 2). Method of administration Teriparatide SUN should be administered once daily by subcutaneous injection in the thigh or abdomen.
6). How to use Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen is also available to instruct patients on the correct use of the pen.
Summary of the safety profile The most commonly reported adverse reactions in patients treated with Teriparatide SUN are nausea, pain in limb, headache and dizziness. 5 % of the placebo patients reported at least 1 adverse event. The adverse reactions associated with the use of teriparatide in osteoporosis clinical trials and post- marketing exposure are summarised in the table below.
The following convention has been used for the classification of the adverse reactions: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1 000 to <1/100), rare (≥ 1/10 000 to <1/1 000) very rare (<1/10 000). 25 mmol/l Psychiatric disorders Common: Depression Nervous system disorders Common: Dizziness, headache, sciatica, syncope Ear and labyrinth disorders Common: Vertigo Cardiac disorders Common: Palpitations Uncommon: Tachycardia Vascular disorders Common: Hypotension Respiratory, thoracic and mediastinal disorders Common: Dyspnoea Uncommon: Emphysema Gastrointestinal disorders Common: Nausea, vomiting, hiatus hernia, gastroesophageal reflux disease Uncommon: Haemorrhoids Skin and subcutaneous tissue disorders Common: Sweating increased Musculoskeletal and connective tissue disorders Very common: Pain in limb Common: Muscle cramps Uncommon: Myalgia, arthralgia, back cramp/pain* Renal and urinary disorders Uncommon: Urinary incontinence, polyuria, micturition urgency, nephrolithiasis Rare: Renal failure/impairment General disorders and administration site conditions Common: Fatigue, chest pain, asthenia, mild and transient injection site events, including pain, swelling, erythema, localised bruising, pruritis and minor bleeding at injection site Uncommon: Injection site erythema, injection site reaction Rare: Possible allergic events soon after injection: acute dyspnoea, oro/facial oedema, generalised urticaria, chest pain, oedema (mainly peripheral) Investigations Uncommon: Weight increased, cardiac murmur, alkaline phosphatase increase *Serious cases of back cramp or pain have been reported within minutes of the injection.
Traceability In order to improve the traceability of biological medicinal products, the name and batch number of the administered medicinal product should be clearly recorded. Serum and urine calcium In normocalcaemic patients, slight and transient elevations of serum calcium concentrations have been observed following teriparatide injection.
Serum calcium concentrations reach a maximum between 4 and 6 hours and return to baseline by 16 to 24 hours after each dose of teriparatide. Therefore, if blood samples for serum calcium measurements are taken, this should be done at least 16 hours after the most recent Teriparatide SUN injection.
Routine calcium monitoring during therapy is not required. Teriparatide SUN may cause small increases in urinary calcium excretion, but the incidence of hypercalciuria did not differ from that in the placebo-treated patients in clinical trials.
Urolithiasis Teriparatide SUN has not been studied in patients with active urolithiasis. Teriparatide SUN should be used with caution in patients with active or recent urolithiasis because of the potential to exacerbate this condition.
Orthostatic hypotension In short-term clinical studies with Teriparatide SUN, isolated episodes of transient orthostatic hypotension were observed. Typically, an event began within 4 hours of dosing and spontaneously resolved within a few minutes to a few hours.
When transient orthostatic hypotension occurred, it happened within the first several doses, was relieved by placing subjects in a reclining position, and did not preclude continued treatment. Renal impairment Caution should be exercised in patients with moderate renal impairment.
1). Treatment should only be initiated if the benefit clearly outweighs risks in this population. Women of childbearing potential should use effective methods of contraception during use of Teriparatide SUN. If pregnancy occurs, Teriparatide SUN should be discontinued.
6) - pre-existing hypercalcaemia - severe renal impairment - metabolic bone diseases (including hyperparathyroidism and Paget’s disease of the bone) other than primary osteoporosis or glucorticoid-induced osteoporosis. - unexplained elevations of alkaline phosphatase - prior external beam or implant radiation therapy to the skeleton - patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Teriparatide in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Description of selected adverse reactions In clinical trials the following reactions were reported at a ≥ 1 % difference in frequency from placebo: vertigo, nausea, pain in limb, dizziness, depression, dyspnoea. Teriparatide SUN increases serum uric acid concentrations.
7 % of placebo patients. However, the hyperuricemia did not result in an increase in gout, arthralgia, or urolithiasis. 8 % of women receiving Teriparatide SUN. Generally, antibodies were first detected following 12 months of treatment and diminished after withdrawal of therapy.
There was no evidence of hypersensitivity reactions, allergic reactions, effects on serum calcium, or effects on Bone Mineral Density (BMD) response. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
3). Until further clinical data become available, the recommended treatment time of 24 months should not be exceeded. Sodium This medicinal product contains less than 1 mmol sodium (23 mg) per maximum daily dose, that is to say ‘sodium- free’.